TW Mason
YOU?
Author Swipe
View article: P203 Effectiveness of anti-IL4R therapy following Suboptimal Response to anti-IL5/5R therapy in severe eosinophilic asthma
P203 Effectiveness of anti-IL4R therapy following Suboptimal Response to anti-IL5/5R therapy in severe eosinophilic asthma Open
Introduction Dupilumab is an anti-IL4R monoclonal antibody (mAb) with proven efficacy in severe eosinophilic asthma (SEA). We previously reported that a suboptimal response to the eosinophil-targeting anti-IL5/5R mAbs mepolizumab and benra…